NEWS
May 30, 20244, 2023
Exciting News – Interview with Our CTO on Revolutionary Blood Clot Treatment
We are thrilled to announce that our Chief Technology Officer, Keitaro Yoshimoto, was recently featured in an interview with Drug Discovery News, discussing groundbreaking advancements in synthetic DNA for safer blood clot treatments. The full article can be read here.
https://www.drugdiscoverynews.com/synthetic-dna-provides-a-safer-blood-clot-treatment-15938
August 22, 2023
Breakthrough Anticoagulant Treatment Showcases Power of MACE® Technology (LinkBIO.Co.LTD Patent)
The recent news release by the University of Tokyo unveils a groundbreaking DNA-based anticoagulant therapy, representing a significant stride in the fight against blood clots. Employing the innovative MACE® technology, this pioneering solution demonstrates the capability of harnessing DNA molecules to develop advanced medical interventions. With the potential to revolutionize anticoagulant treatments, this achievement underlines the power of MACE® in driving medical innovation. To learn more about this remarkable breakthrough, read the full press release
Press release link: https://www.u-tokyo.ac.jp/focus/en/press/z0508_00307.html
Additional links:
https://www.eurekalert.org/news-releases/999069
https://www.alphagalileo.org/en-gb/Item-Display/ItemId/236585
August 1, 2023
Our researcher, Osman Waleed, and Tokyo University’s CTO, Associate Professor Keitaro Yoshimoto, have announced their research achievement entitled ‘Steric hindrance and structural flexibility shape the functional properties of a guanine-rich
oligonucleotide’ published in Nucleic Acids Research with an impact factor of 19. The study elucidates the factors behind the most potent anticoagulant activity in nucleic acid aptamers obtained through the MACE®-SELEX method. The
press release was issued by Tokyo University.
Press release link:
https://www.u-tokyo.ac.jp/focus/ja/press/z0109_00089.html?fbclid=IwAR01tXMHgen5GWPH-5NMObALj2oI_pGvbES3Mv8I7KMZ5Rpq3zcQqSF7Im0
Dec 02, 2022
We have published our new research paper to prove the efficiency of our MACE SELEX Technology for the selection of highly specific DNA Aptamer for small molecules target.
Paper Title: Discovery of a Highly Specific Anti-methotrexate (MTX) DNA Aptamer for Antibody-Independent MTX Detection.
Journal: Journal of Analytical Chemistry.
Paper Link:
Discovery of a Highly Specific Anti-methotrexate (MTX) DNA Aptamer for Antibody-Independent MTX Detection | Analytical Chemistry (acs.org)
July 25, 2022
We are pleased to announce that LinkBIO and Nara Medical University [Medicinal Biology of Thrombosis and Hemostasis Research Group] have entered into a joint research and development agreement on nucleic acid discovery for the treatment
of Blood Diseases”.
The agreement brings together the power of LinkBIO MACE® technology and Nara Medical University’s experience in the area of blood diseases to accelerate the discovery of a novel nucleic acid therapy.
寄付講座等のご紹介｜奈良県立医科大学小児科 (naramed-u.ac.jp)
June 01, 2022
it is our pleasure to announce the joint research collaboration between LinkBIO and HitGen to improve drug discovery screening platform for small molecules. The agreement brings together the power of LinkBIO MACE® technology and HitGen experience in DNA-encoded chemical libraries (DELs) to accelerate the discovery of Small Molecules-Based Therapy.
May 13, 2022
We are pleased to announce that Nikkei Biotechnology has published the latest article on MACE® Tech for Aptamer Screening which includes commentary from our CTO Professor Keitaro Yoshimoto.
For more information about article content, please visit the following link;
https://bio.nikkeibp.co.jp/atcl/column/16/021500017/042100238/
March 1, 2022
Funakoshi has published a new article about LinkBIO MACE® Technology for Aptamers Separation and how it could accelerate both Therapeutics and Diagnostics Discovery P5~7).
For more information about article content, please visit the following link;
https://fnkprddata.blob.core.windows.net/domestic/news/220501pdf/220501.pdf
February 18, 2022
We are happy to announce that we successfully got our MACE® Trademark Registration (Trademark Registration No. 6515690).
December 15, 2021
We are pleased to announce the Grant of Japan Patent No. 6994198 for “Methods for screening nucleic acid aptamers”.
December 1, 2021
We are pleased to announce that we have entered into a Strategic Alliance Agreement with Funakoshi.
LinkBIO Co.Ltd and Funakoshi Company announced today that the companies have entered into a strategic alliance that will allow Funakoshi to open new sales channels for LinkBIO MACE® Technology for Aptamer Screening.
The agreement brings together the power of LinkBIO MACE® technology and the strong networking of Funakoshi in the life science area to promote the businesses of both companies in the area of diagnostics and therapeutics discovery.
Customers of LinkBIO will now be able to get Aptamer screening services through Funakoshi.
Please follow the following link for more details about the Funakoshi business;
https://www.funakoshi.co.jp/
We will continue to strengthen our collaboration with distributors and work to penetrate and expand sales of our services and products in the Japanese and overseas markets.
October 13, 2021
LinkBIO Co., Ltd. and Maruho Co., Ltd. have signed a “Joint Research and Development Agreement on Diagnostics”. By combining the unique technologies of them, we aim to discover new seeds and further improve the development of their
applications in the drug discovery target area, which has been considered difficult using conventional methods and approaches.
For more information on the business of Maruho, please refer to the following website.
https://www.maruho.co.jp/
July 22, 2021
Article entitled “Accelerated Discovery of Potent Bioactive anti-TNFα Aptamers by Microbead-Assisted Capillary Electrophoresis (MACE)-SELEX” was accepted to ChemBioChem. In the present paper, using MACE-SELEX, fifteen DNA aptamers
against TNF-a were identified and discovered ones which binding affinity were higher than previously reported aptamer.
DOI: 10.1002/cbic.202100478
July 21, 2021
Patent “Methods for screening nucleic acid aptamers” is granted in China (
ZL201780007417.2)
September 1, 2021
Appointment of new Consultant : Dr. Koji Wakui (Researcher, DAIICHI SANKYO COMPANY, LIMITED)
July 15, 2021
Ibaraki Challenge Fund awarded (1st round in 2021)
Jun 21, 2021
Patent “Methods for screening nucleic acid aptamers” is granted in Taiwan (
I731028)
April 13, 2021
Patent “Methods for screening nucleic acid aptamers” is granted in USA (
US10975370)
March 6, 2021
Appointment of new Managing Director and Chief Technology Officer (CTO): Dr. Keitaro Yoshimoto (Associate Professor, The University of Tokyo; and LinkBIO’s Technology Advisor)
January 22, 2021
Micro business sustainability subsidy awarded (3rd round in FY2020)
December 22, 2020
In connection with business expansion, LinkBIO’s HQ moved to Maeda Corporation’s ICI Center (5270 Terada, Toride-shi, Ibaraki Prefecture).
October 19, 2020
Announcement of press release for J-KISS-type fundraising by Samurai Incubate, Inc.
October 10, 2020
Recruitment of new technical staff for R&D and screening (drug discovery research support)
As of January 2021, recruitment temporarily suspended.
August 1, 2020
Signing of collaborative research contract with The University of Tokyo’s Dept. of Multidisciplinary Sciences (Graduate School of Arts and Sciences; Meguro-ku, Tokyo).